Page 245 - Bloedstollig en bloedingsneiging

XV
‘[I]n cases of myocardial infarction that survive the initial impact of the attack, anticoagulants, correctly used, help to prevent both thrombo-embolic com- plications and deaths. ... The therapy is not one for the careless, or for the physician who does not fully understand the objective, methods, and contra- indications of the technique.’
Irving S. Wright, et al. (1954)1
‘Zeer veel van de kennis en ervaring van de trombosedienst is autodidactisch. Het werk van de dienst heeft echter in het moderne samenspel tussen patiënt, huisarts en specialisten een niet meer weg te denken plaats ingenomen.’
Fredi Loeliger (1971)2
‘[T]hrombosis was believed to be clotting in the wrong place, so an anti- coagulant drug seemed likely to be antithrombotic. ... survival is directly re- lated to the actual process of thrombosis and embolisation. The situation in co- ronary disease is infinitely more complex but as this was not recognised when anticoagulants became available the end-points used in early studies reflected this naivete. An unwritten series of equations dominated everyone’s thinking: death = myocardial infarction; myocardial infarction = coronary thrombosis; coronary thrombosis = coronary blood coagulation; therefore anticoagulants = prevention of death in coronary disease. None of these equations tells the whole story.’
J.R.A. Mitchell (1981)3
‘Nergens ter wereld [als in Nederland] verheugt anticoagulatie zich in zo een wetenschappelijke en practische belangstelling, nergens ter wereld verschijnen per hoofd van de bevolking zoveel proefschriften over bloedstolling, nergens ter wereld - bijna nergens - vindt men zulke honorabele, eerlijke, geleerde, hooggeleerde en emotionele tegenstanders van deze behandelingsmethodiek.’
Han Roos (1981)4